Securities Antitrust Consumer Fraud Structured Finance Whistleblower/Qui Tam Corporate Governance Mergers & Acquisitions ERISA Healthcare Fraud
PartnersOf Counsel Associates Staff Attorneys All
M & A Investigations New Federal Securities Cases Current CasesSettlements & Class Notices Accolades
Our Institutional Monitoring Service Our ProcessReporting Custom Monitoring
Articles Press Releases Television
Contact Us Join a Class Action Report a Fraud

New Federal Securities Cases

Intra-Cellular Therapies, Inc.

A class action lawsuit has been filed in the United States District court for the Eastern District of New York against Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ:ITCI), on behalf of investors who purchased or otherwise acquired Intra-Cellular securities during the period from August 12, 2014 through April 28, 2017 (the "Class Period"). The lawsuit seeks to recover damages for Intra-Cellular investors under the federal securities laws.

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that develops drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The lawsuit asserts that defendants failed to disclose that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed, and these findings posed an additional safety concern regarding lumateperone.

On May 1, 2017, the Company revealed that the FDA raised questions with some of its drug studies. On this news, the stock price fell from $13.82 to $10.49 per share, damaging investors.

If you acquired Intra-Cellular securities during the Class Period, you may, no later than July 11, 2017, request that the court appoint you lead plaintiff of the proposed class. Although your ability to share in any recovery is not affected by the decision whether or not to seek appointment as a lead plaintiff, lead plaintiffs make important decisions that could affect the overall recovery for class members, including decisions concerning settlement.

If you are a current or former Intra-Cellular shareholder and wish to obtain additional information, please fill out the contact form at the link below.

Investigation Contact Form

Intra-Cellular Therapies, Inc. Contact Form


Ira M. Press
Ira M. Press

Kirby McInerney LLP | 825 Third Avenue | NYC 10022 | Tel. 212.371.6600 | Fax 212.751.2540

Attorney Advertising - Prior Results do not Guarantee a Similar Outcome

Law Firm Website Design by Business Edge